Eli Lilly 2012 Annual Report Download - page 35

Download and view the complete annual report

Please find page 35 of the 2012 Eli Lilly annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 164

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • 74
  • 75
  • 76
  • 77
  • 78
  • 79
  • 80
  • 81
  • 82
  • 83
  • 84
  • 85
  • 86
  • 87
  • 88
  • 89
  • 90
  • 91
  • 92
  • 93
  • 94
  • 95
  • 96
  • 97
  • 98
  • 99
  • 100
  • 101
  • 102
  • 103
  • 104
  • 105
  • 106
  • 107
  • 108
  • 109
  • 110
  • 111
  • 112
  • 113
  • 114
  • 115
  • 116
  • 117
  • 118
  • 119
  • 120
  • 121
  • 122
  • 123
  • 124
  • 125
  • 126
  • 127
  • 128
  • 129
  • 130
  • 131
  • 132
  • 133
  • 134
  • 135
  • 136
  • 137
  • 138
  • 139
  • 140
  • 141
  • 142
  • 143
  • 144
  • 145
  • 146
  • 147
  • 148
  • 149
  • 150
  • 151
  • 152
  • 153
  • 154
  • 155
  • 156
  • 157
  • 158
  • 159
  • 160
  • 161
  • 162
  • 163
  • 164

23
Part II
Item 5. Market for the Registrant’s Common Equity, Related
Stockholder Matters, and Issuer Purchases of Equity
Securities
You can find information relating to the principal market for our common stock and related stockholder
matters at Item 8, "Financial Statements and Supplementary Information—Selected Quarterly Data
(unaudited)” and “Selected Financial Data (unaudited).” That information is incorporated here by reference.
The following table summarizes the activity related to repurchases of our equity securities during the fourth
quarter ended December 31, 2012:
Period
Total Number of
Shares Purchased
(in thousands) Average Price Paid
per Share
Total Number of Shares
Purchased as Part of
Publicly Announced
Plans or Programs
(in thousands)
Approximate Dollar Value
of Shares that May Yet Be
Purchased Under the
Plans or Programs
(dollars in millions)
October 2012. . . . . . — $ — — $ 419.2
November 2012. . . . 8,772 47.77 8,772 —
December 2012. . . . 8,146 49.09 8,146 1,100.0
Total. . . . . . . . . . . . . 16,918 48.40 16,918
In March 2000, we announced a $3.00 billion share repurchase program. During November 2012, we
completed the $3.00 billion share repurchase program with the share purchase of $419.2 million. In
December 2012, we announced a $1.50 billion share repurchase program. During December 2012, we
repurchased $400.0 million of shares, and, as a result, $1.10 billion remains to be purchased under this
program.
Item 6. Selected Financial Data
You can find selected financial data for each of our five most recent fiscal years in Item 8 under “Selected
Financial Data (unaudited).” That information is incorporated here by reference.
Item 7. Management’s Discussion and Analysis of Results of
Operations and Financial Condition
RESULTS OF OPERATIONS
Executive Overview
This section provides an overview of our financial results, recent product and late-stage pipeline
developments, and legal, regulatory, and other matters affecting our company and the pharmaceutical
industry. Earnings per share (EPS) data is presented on a diluted basis.